CommercialCoverageMedium impact
Transcatheter Pulmonary Valve Implantation (CPB 0821, reviewed 2026-04-22)
Aetna·Cardiology, Cardiothoracic Surgery, Pediatrics·Surgery
Effective date
Apr 22, 2026
We identified it
Aug 18, 2026
Summary
Aetna's updated CPB 0821 (effective 2026-04-22) clarifies medical necessity criteria for transcatheter pulmonary valve implantation using FDA-approved devices (Harmony, Melody, Sapien S3). Coverage requires specific RVOT conduit dysfunction criteria (stenosis ≥35 mm Hg gradient or moderate-to-severe regurgitation) with minimum 16 mm conduit diameter, or non-conduit patch-repaired RVOT, or pulmonary insufficiency with RV dilation post-failed valvulectomy. Valve-in-valve implantation and other off-label indications remain experimental/investigational and non-covered.
Action Required
By 2026-04-22: Billing team must update prior authorization protocols and claims adjudication rules in billing software to enforce strict medical necessity criteria for CPT 33477. Specifically: (1) Require documentation of RVOT conduit diameter ≥16 mm and either stenosis with mean gradient ≥35 mm Hg OR moderate-to-severe regurgitation before processing claims; (2) Flag claims for non-conduit patch-repaired RVOT or pulmonary insufficiency with progressive RV dilation post-failed valvulectomy as covered when criteria met; (3) Deny or refer to medical review any claims for valve-in-valve implantation or other off-label indications as experimental/investigational; (4) Update prior auth templates and encounter forms to require providers document specific hemodynamic measurements and conduit specifications per policy. Providers must include appropriate ICD-10 diagnosis codes (I37.1, I51.7, or complication codes T82.09XA-T82.897S) to support medical necessity. Failure to enforce criteria will result in claim denials and potential recovery actions from Aetna.